Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Paris  >  Valneva SE    VLA   FR0004056851

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 

VIVALIS : MISE A DISPOSITION DU DOCUMENT DE REFERENCE 2011

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/27/2012 | 07:35am CET

VIVALIS PUBLIE SON
DOCUMENT DE REFERENCE 2011

Nantes, Lyon (France) - 27 avril 2012 : VIVALIS (NYSE Euronext Paris : VLS), société biopharmaceutique, annonce que son Document de référence 2011 a été déposé le 25 avril 2012 auprès de l'Autorité des Marchés Financiers (AMF) sous le numéro D12-0412.

Des exemplaires du présent Document de Référence sont disponibles sans frais auprès de la Société, au 6, rue Alain Bombard, 44821 Saint-Herblain cedex, ainsi qu'en version électronique sur le site internet de la Société (www.vivalis.com) et  sur le site internet de l'Autorité des marchés financiers (www.amf-france.org:
http://www.amf-france.org/).

Les documents suivants sont notamment intégrés dans le document de référence 2011 :
-       le rapport financier annuel,
-       le rapport du Président du Conseil de surveillance sur les conditions d'organisation et de préparation des travaux du Conseil de surveillance et sur les procédures de contrôle interne mises en place par la Société,
-       les informations relatives aux honoraires versés aux commissaires aux comptes,
-       le document d'information annuel.

VIVALIS MISE A DISPOSITION DU DOCUMENT DE REFERENCE:
http://hugin.info/143334/R/1606613/509370.pdf



This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: VIVALIS via Thomson Reuters ONE

HUG#1606613
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on VALNEVA SE
02/23 VALNEVA : Reports Strong Q4 and FY 2016 Business Performance; Expects Further Gr..
02/17 VALNEVA : Supports World Encephalitis Day on February 22, 2017
01/05 VALNEVA : Announces a New Research License Agreement with MSD Animal Health for ..
01/05 VALNEVA : Announces New Research License Agreement with MSD Animal Health for De..
2016 VALNEVA : Confirms Closing of Private Placement in Connection with €15.2m Invest..
2016 VALNEVA : Valneva Receives FDA and European Approvals to Start Clinical Testing ..
2016 VALNEVA : Receives FDA and European Approvals to Start Clinical Testing of Lyme ..
2016 VALNEVA : Leading Healthcare Investor MVM Life Science Partners Acquires 7.5% Sh..
2016 VALNEVA : Leading Healthcare Investor MVM Life Science Partners Acquires 7.5% Sh..
2016 VALNEVA : Wins "Fastest Growing Listed Company" Tech 50 Award for France by Delo..
More news
Sector news : Biotechnology & Medical Research - NEC
02/27DJSANOFI : Lonza to Invest CHF290 Million in New Plant in Switzerland
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
More sector news : Biotechnology & Medical Research - NEC
Advertisement
Financials (€)
Sales 2016 99,1 M
EBIT 2016 -38,7 M
Net income 2016 -46,6 M
Debt 2016 41,5 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017 10,60
EV / Sales 2016 2,49x
EV / Sales 2017 2,18x
Capitalization 206 M
More Financials
Chart VALNEVA SE
Duration : Period :
Valneva SE Technical Analysis Chart | VLA | FR0004056851 | 4-Traders
Full-screen chart
Technical analysis trends VALNEVA SE
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Average target price 4,80 €
Spread / Average Target 81%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Thomas Lingelbach President & Chief Executive Officer
Frédéric Grimaud Chairman-Supervisory Board
Reinhard Kandera Chief Financial Officer
Klaus Schwamborn Vice President-Discovery Research & Innovation
James R. Sulat Vice Chairman-Supervisory Board
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
VALNEVA SE-12.95%218
INCYTE CORPORATION30.86%25 385
QUINTILES IMS HOLDINGS..2.09%18 749
CELLTRION, INC.--.--%10 997
LONZA GROUP AG2.04%10 407
SEATTLE GENETICS, INC.18.87%9 393
More Results